

Brain & CNS CANCER PATHWAY BOARD MEETING

MINUTES

DATE: 25/04/2014

Member's attending:

Dr McBain (Chair)	Christie	Dr Sam Kay	UHSM
Julie Emerson	Christie	Andrea Wadseon	Salford
Sara Robson	Christie	Alison Gilston-Hope	Salford
Elizabeth Molloy	Christie	Dr Tran	Christie
Dr Sein	East Cheshire		
Miss Karabatsou	Salford		
Mr Rutherford	Salford		

Apologies

Dr Kallat	Bolton	Dr Douglass	Tameside
Prof Selby	CMFT	Dr Kearney	Salford
Dr Ismail	WWL	Dr Dizayee	Stockport

In attendance J Leighton Manchester cancer

- **Introductions and apologies**

Dr McBain (CMB) welcomed all to the meeting and noted the apologies received.

- **Introduction to Manchester cancer**

CMB outlined the purpose of the pathway board and clarified the only role of members is in reviewing the whole pathway as a stakeholder in improving the outcomes for patients. She stressed that the priority would be to create and maintain an efficient and effective pathway.

- **Board member introductions**

The board members present introduced themselves to the meeting. James Leighton (JL) explained that there would be a patient representative on the board; however their participation would occur after an engagement event to be held in conjunction with Macmillan cancer.

This engagement event is now confirmed to take place on 23rd June. The board asked that they invite identified carers or patients who know the brain/CNS pathway to this event. JL to discuss.

Action – JL to discuss patient invitations with event organisers

There was further discussion on GP representation and Manchester cancer will lead on this.

- **Discussion of board objectives**

A review of the previous GMCCN work schedule (2012-2016) took place. This was to begin the action planning for the pathway board. In a round table discussion there were a number of outline objectives discussed -

- Improved data collection
- Development of pathway board work plan
- Design and deployment of services that will meet the needs of the patients
- Identify opportunities for change
- Maintain the guidelines for brain and CNS cancer

There was a consensus formed that the level of intelligence currently available is something that should be built upon to allow for proper analysis of the pathway. Potential sources of new information that could be used is new data on presentation rates and live audit data from the British base of skull society

There was discussion on the use of the Christie database as a vehicle to gather such data. This was considered as an option and JV agreed to meet with Dr Livesey from the Christie to review.

Action – CMB to meet with Dr Livesey and review the Christie database and report back to next board meeting.

- **Board roles**

In view of the large number of apologies this was deferred until the next meeting.

CMB raised the issue of engagement with the survivorship agenda. There was a lack of clarity on how brain/CNS cancer would be represented on the living with and beyond cancer pathway board. As a consequence JL agreed to progress this within Manchester cancer.

JL – to discuss with Manchester cancer

- **Future meetings**

JL agreed to circulate a meeting date scheduler to help establish the best day and session on which to hold the meeting. It was agreed that all meetings would be held at Salford Royal.

The next meeting is scheduled for the afternoon of July 1st and this will remain. It is planned to hold one more subsequent meeting in this calendar year, with the number of future meetings decided by the board action plan.

Action - JL to send out to all board members

- **Educational event**

Board members were asked to consider holding an educational event on brain and CNS cancer as part of their work plan. Members agreed to consider both the topic of the meeting and the target audience. This is to be discussed at the next board meeting.

Action - JL to put on agenda of next board meeting.

- **Any other business**

There was no other business discussed

- **Date & Venues for Future Meetings**

The next meeting of the board will be on **Tuesday 1st July 1.30pm, Seminar room 6 Mayo building, SRFT**